BIOPHARMACEUTICAL COMPANY
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launch
Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to launch Pebrilzo in early 2027 in the UK and EU, and in late 2028 in the US. In response to Genentech's patent infringement suit, the New Jersey court dismissed the case at Genentech's request. The details of the settlement agreement remain confidential between the companies involved.
Biocon clears path for cancer drug launch
Biocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing legal disputes between the two companies in jurisdictions such as the US and Canada. Under the terms, Biocon can launch Pebrilzo in the EU and UK by early 2027 and in the US by Q3 of 2028. Other global launches are planned between 2026 and 2028, depending on regulatory approvals.
When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%
Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends on what it chose in the last five or six. So, one name can do wonderfully while the one sitting next to it does very little. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
Kiran Mazumdar-Shaw has a career lesson from 3 Nobel prize winners as AI forces layoffs and changes jobs across the world
Biocon chairperson Kiran Mazumdar-Shaw shared a message on persistence from three 2023 Nobel Prize winners as AI reshapes jobs and companies rethink their workforces. Her post highlighted the importance of finding reasons to keep going despite setbacks, a message that resonates with workers facing career uncertainty, layoffs and changing skill requirements.
Ichor Biologics seeks $80-100 million PE funding for minority stake sale
Ichor Biologics is seeking eighty to one hundred million dollars from private equity investors. The Hyderabad-based company operates in the specialized plasmatherapy segment. Promoters Ananda Reddy Sudini and Sujana Sudini hold significant stakes in the firm. Ichor manufactures therapeutic protein products derived from human plasma. The company's products serve various critical therapeutic areas.
- Go To Page 1

5 stocks with consistent score improvement and upside potential of up to 22% in 1 year, according to analysts
Given the current situation both globally and domestically, one can expect more headwinds in the market. There is, on the domestic front, an element of hope as well: The festive season that is almost upon us. Will it provide the tailwind the market is waiting for?

MSD inaugurates 2.5 lakh sq ft tech centre in Hyderabad
Global biopharmaceutical company MSD has opened a new technology centre in Hyderabad. This facility will enhance the company's digital, data, and AI capabilities. The centre supports MSD's global Human Health business operations. Telangana's minister highlighted Hyderabad's evolving life sciences ecosystem.

Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely seller
Biocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 crore shares, or about 1% stake, for around Rs 638 crore at a floor price of Rs 385 per share, implying a discount of up to 1.9% to the market price. The seller will face a 30-day lock-up on further stake sales.

Biocon shares: Active Pine may divest up to 1% equity worth Rs 638 crore via block deal
Active Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share. The development comes alongside Biocon’s Brazil partnership for Pertuzumab under a 10-year programme.

Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the country’s PDP programme, providing access to around 70% of public-sector demand.

Not an animal, but one popular fruit shares 60% of human genes. Genetic expert says it’s not shocking: ‘There’s a lot of things we do the same way…'
Who doesn’t like to munch on a banana or two during the summer? Although a guilty pleasure for those with high blood sugar levels, it remains a favourite snacking item. However, apart from being our comfort food, bananas and us are also genetically related. According to a genome study that came out in 2013, we share 60% of our DNA with this yellow fruit!

Global Market: China, Hong Kong stocks rise as AI rebound boosts investor sentiment
On Wednesday, stocks in China and Hong Kong surged, reflecting a favourable global market environment. Technology and artificial intelligence supply-chain companies attracted significant investor interest. Alibaba shares rose after the company’s chairman purchased additional stock.

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion
British drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Discussions are ongoing, with an agreement potentially this week. This move comes amid a surge in biotech acquisitions as large companies seek to boost their drug pipelines. Nuvalent focuses on targeted cancer therapies.

Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal
Bayer is set to acquire Perfuse Therapeutics in a deal valued up to $2.45 billion. This strategic move aims to enhance Bayer's eye care treatments. The acquisition includes PER-001, a promising drug for glaucoma and diabetic retinopathy currently in clinical trials. This development signifies a significant step forward in eye disease treatment.

Bengaluru horror: 35-year-old woman allegedly gang-raped by four, then fled away with refrigerator, washing machine and LED TV
In a shocking incident in southeast Bengaluru, a 35-year-old woman was gang-raped at her friend's house by four men. The perpetrators, after the assault, stole Rs 13,000 via online transfer and further looted the house, taking away a refrigerator, washing machine, and LED TV. Police have arrested the accused, who are in their late 20s and work in various professions.

Biocon raises Rs 4,500 crore through successful QIP
Biocon, a leading biopharmaceutical company, successfully raised Rs 4,500 crore through QIP. This marks their first equity funding since 2004. The QIP saw strong interest from domestic and international investors. The raised capital will be used to purchase debentures and repay borrowings. Kotak Mahindra Capital, BofA India Securities, and Goldman Sachs (India) Securities managed the QIP.

MSD Pharma, Delhi Capitals partner to create awareness about cervical cancer prevention
MSD Pharmaceuticals and Delhi Capitals have partnered to raise cervical cancer prevention awareness in India. The women's T20 team will display this message on their jerseys during matches. The initiative aims to reduce stigma, provide information accessibility, and promote preventive health measures. Cervical cancer remains a major issue in India with many cases diagnosed annually.

PlasmaGen Biosciences raises Rs 225 crore in equity funding
The Bengaluru-based startup will use the proceeds to boost growth of plasma products. It is also expected to use the corpus to expand its presence internationally, develop products and fund working capital requirements.

Sun Pharma completes acquisition of Concert Pharmaceuticals
The drug major has successfully completed the acquisition of Concert Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company that is developing deuruxolitinib for the potential treatment of adult patients with moderate to severe alopecia areata, Sun Pharma said in a regulatory filing.

Bristol Myers Squibb to invest Rs 800 crore to set up facility in Hyderabad for drug development, IT
The company plans to begin operations in Hyderabad later in 2023, with the potential over the next few years to employ approximately 1,500 people who will be engaged in cutting-edge Research and Development and digital activities, a BMS release said.

Devastated to lose my husband: Kiran Mazumdar-Shaw
"I am devastated to lose my husband, my mentor and soul mate. I will always be spiritually guided by John as I pursue my purpose. Rest in Peace my darling John. Thank you for making my life so very special. I will miss you profoundly," Mazumdar-Shah said.

CCI clears Phoenix Parentco's acquisition of Parexel International Corporation
The proposed transaction pertains to acquisition of 100 per cent of the equity shareholding of Parexel International, according to a notice filed with the regulator. "Commission approves acquisition of Parexel International Corporation by Phoenix Parentco, Inc," the watchdog said in a tweet on Monday.

CSIR-IICT, Bengaluru pharma firm join hands to manufacture anti-COVID drug 2-DG
The CSIR-Indian Institute of Chemical Technology (IICT) here and Bengaluru-based Anthem Biosciences Pvt Ltd have entered into an agreement for technology transfer and manufacture of anti- COVID drug 2-DG.

Alembic Pharma arm inks pact with Curon to develop cancer treatment drug in Greater China
As per the agreement, Rhizen will receive an undisclosed upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of USD 149.5 million plus double-digit royalties.

Gilead nears deal to buy Immunomedics for more than $20 billion: Report
A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer called Metastatic Triple-Negative Breast Cancer, could be announced Monday if not sooner, the Wall Street Journal said, citing people familiar with the matter.

Kiran Mazumdar Shaw bats for easing regulations on biotechnology sector
"The erstwhile UPA regime and the present Modi government have taken some good steps, but have not done enough to improve the economy," Shaw said.
Pharmaceutical Export Promotion Council of India seeks clarity from US on new generic drug fee norms
Pharmexcil has sought clarity from the United States Food and Drug Administration (USFDA ) on the new generic drug user fee norms.
Load More